Autoimmune Neurosensory Hearing Loss (ANSHL) Clinical Trial
Official title:
A Pilot Trial of Rilonacept for Treatment of Autoimmune Neurosensory Hearing Loss
This study is an open label proof of concept study of rilonacept for patients with ANSHL
| Status | Recruiting |
| Enrollment | 10 |
| Est. completion date | March 2018 |
| Est. primary completion date | March 2018 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 75 Years |
| Eligibility |
Inclusion Criteria: 1. The presence of progressive sensironeural hearing loss greater than or equal to 30 dB in both ears at one or more frequencies (250, 500, 1000, 2000, 3000, 4000, 6000 or 8000 Hz) and idiopathic-based on clinical evaluation, blood tests, and radiographic imaging. 2. Documented improvement in hearing by audiogram after 30 days of treatment with high dose prednisone 40-60 mg/d. Improvement is defined by 10 dB improvement in pure tone average (500-3000 dB) or an improvement in word identification score of at least 12% in either ear (both relative to baseline). Prednisone could be started at screening but patients may have received prednisone prior to screening and the pre prednisone audiogram will be used as the screening audiogram for this study. It is expected the majority of these patients will screen for the study in this fashion as they are referred from otoloaryngology after initial treatment. 3. 18-75 years of age 4. Able and willing to give written informed consent and comply with the requirements of the study protocol 5. Negative serum pregnancy test (for women of child bearing potential). Males and Females of child bearing potential must agree to consistently use 2 forms of highly effective birth control (at least 1 of which must be a barrier method) starting at screening and throughout the study period and for 3 months after the final study drug administration. Exclusion Criteria: 1. Pregnant or nursing, or planning to become pregnant or father a child within 3 months after receiving the last dose of study drug 2. Have a known or suspected current active infection or a history of chronic or recurrent infectious disease including, but not limited to, chronic renal infection, chronic chest infections, chronic sinusitis, recurrent urinary tract infections, an open, draining, infected skin wound. 3. Within 2 months of first study drug administration, have had a serious infection, have been hospitalized for an infection, have been treated with PO antibiotics for longer than 2 weeks, or have been treated with intravenous (IV) antibiotics for an infection 4. Uncontrolled diabetes at the baseline visit (defined as HbA1c =9.0%) 5. Patients requiring dialysis 6. Patients who have had an organ transplant 7. Treatment with any systemic {non-glucocorticoid} immunosuppressants (e.g. methotrexate, azathioprine, cyclosporine, mercaptopurine, mycophenolate mofetil, tacrolimus, sirolimus within 4 weeks of baseline rilonacept administration. No leflunomide treatment within 8 weeks prior to baseline administration. No etanercept, adalimumab, infliximab, tocilizumab, abatacept, or natalizumab, within 2 months prior to baseline visit; No rituxan for 12 months prior to baseline and evidence of normal B cell count required. Patients previously treated with anakinra for ANSHL cannot be enrolled. 8. Prohibited Medications: 1. Strong CYP3A4 inhibitors, protease inhibitors or P-gp inhibitors. 2. Long-acting or extended release forms of opiates. 3. Live or live-attenuated vaccines are excluded during the course of the study 4. IA and IM glucocorticoid injections. Long-acting steroid preparations are not allowed during study (this includes suspensions and all forms of dexamethasone). 9. History of a demyelinating disease or symptoms suggestive of multiple sclerosis 10. Treatment with a live or live-attenuated virus vaccine during the 3 months prior to baseline 11. Estimated glomerular filtration rate (eGFR) of <20 mL/min/1.73m2 or patients planning to start dialysis within a year from the screening visit 12. Baseline laboratory test results meeting any of the following criteria: 1. Hemoglobin (Hgb)<8.5 g/dL (85 g/L) 2. Neutrophil count<1.5 x 103/µL 3. Platelet count<100 x 103/µL 4. Total bilirubin exceeding 1.5 times the upper limit of normal (ULN) unless consistent with Gilbert's syndrome 5. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) exceeding 2 times the ULN 13. Positive history of human immunodeficiency virus (HIV) by clinical or serological testing. 14. Presence of hepatitis B surface antigen (HBsAg) and/or hepatitis C antibody (HCV) by serologic testing 15. History of active TB prior to screening or chest x-ray showing evidence of malignancy or any abnormalities suggestive of prior tuberculosis (TB) infection, including, but not limited to, apical scarring, apical fibrosis, or multiple calcified granulomata. 16. A positive intradermal skin tuberculin test (purified protein derivative [PPD] 5 tuberculin unit [TU]) of =5 mm induration read at 48 to 72 hours or positive QuantiFERON-gold testing. Signs or symptoms suggestive of active TB (e.g. new cough lasting >14 days or a change in chronic cough, persistent fever, unintentional weight loss, night sweats) upon review of medical history and/or physical examination. If the patient is thought to have a false-positive PPD because of prior BCG vaccination and it is known that the patient has been negative on testing obtained outside the protocol for M. tuberculosis infection using a cell-based interferon gamma assay the patient is eligible for enrollment. 17. Recent close contact with a person with active TB 18. History of latent untreated TB. Patients who have been adequately treated for latent TB are eligible for enrollment. 19. Any other medical condition that in the opinion of the investigator could adversely affect the patient's participation or interfere with evaluations. This includes significant concomitant illness such as, but not limited to, cardiac, renal, neurological, endocrinological, metabolic, pulmonary, gastrointestinal, or psychiatric disease. 20. History or presence of malignancy within 5 years of the screening visit (other than a successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix) 21. History of a myeloproliferative disorder 22. History of alcohol abuse within last 5 years or current intake of 21 or more alcohol-containing drinks per week 23. History of drug abuse within the 5 years prior to screening 24. Patients with previous exposure to rilonacept 25. Use of any investigational drug within 30 days or within 5 half-lives (whichever is longer) prior to the screening visit 26. Sexually active men or women of childbearing potential who are unwilling to practice adequate contraception during the study (adequate contraceptive measures are defined as the use of two highly effective forms of birth control, include stable use of oral contraceptives or other prescription pharmaceutical contraceptives; intrauterine device; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly) 27. Known moderate-to-severe liver disease (Child-Pugh class B or C) 28. Known hypersensitivity to CHO cell derived therapeutics or proteins or any components of rilonacept |
| Country | Name | City | State |
|---|---|---|---|
| United States | Metroplex Clinical Research Center | Dallas | Texas |
| Lead Sponsor | Collaborator |
|---|---|
| Stanley Cohen | Regeneron Pharmaceuticals |
United States,
Bouman H, Klis SF, Meeuwsen F, de Groot JC, Smoorenburg GF, Veldman JE. Experimental autoimmune inner ear disease: an electrocochleographic and histophysiologic study. Ann Otol Rhinol Laryngol. 2000 May;109(5):457-66. — View Citation
Broughton SS, Meyerhoff WE, Cohen SB. Immune-mediated inner ear disease: 10-year experience. Semin Arthritis Rheum. 2004 Oct;34(2):544-8. — View Citation
Cohen S, Roland P, Shoup A, Lowenstein M, Silverstein H, Kavanaugh A, Harris J. A pilot study of rituximab in immune-mediated inner ear disease. Audiol Neurootol. 2011;16(4):214-21. doi: 10.1159/000320606. Epub 2010 Oct 27. — View Citation
Cohen S, Shoup A, Weisman MH, Harris J. Etanercept treatment for autoimmune inner ear disease: results of a pilot placebo-controlled study. Otol Neurotol. 2005 Sep;26(5):903-7. — View Citation
Harris JP, Sharp PA. Inner ear autoantibodies in patients with rapidly progressive sensorineural hearing loss. Laryngoscope. 1990 May;100(5):516-24. — View Citation
Harris JP, Weisman MH, Derebery JM, Espeland MA, Gantz BJ, Gulya AJ, Hammerschlag PE, Hannley M, Hughes GB, Moscicki R, Nelson RA, Niparko JK, Rauch SD, Telian SA, Brookhouser PE. Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate: a randomized controlled trial. JAMA. 2003 Oct 8;290(14):1875-83. — View Citation
Hirose K, Wener MH, Duckert LG. Utility of laboratory testing in autoimmune inner ear disease. Laryngoscope. 1999 Nov;109(11):1749-54. — View Citation
Kitashara M, Yazawa.Y, Uchida K. Immunoglobulin treatment for advance cases of bilateral Meniere's disease. In: Nadol JB ed. Meniere's disease: pathogenesis, pathophysiology, diagnosis and treatment. Berkeley, Ca: Kugler Publications; 1989; 411-419.
Luetje CM. Theoretical and practical implications for plasmapheresis in autoimmune inner ear disease. Laryngoscope. 1989 Nov;99(11):1137-46. — View Citation
McCabe BF. Autoimmune inner ear disease: therapy. Am J Otol. 1989 May;10(3):196-7. — View Citation
McCabe BF. Autoimmune sensorineural hearing loss. Ann Otol Rhinol Laryngol. 1979 Sep-Oct;88(5 Pt 1):585-9. — View Citation
Moscicki RA, San Martin JE, Quintero CH, Rauch SD, Nadol JB Jr, Bloch KJ. Serum antibody to inner ear proteins in patients with progressive hearing loss. Correlation with disease activity and response to corticosteroid treatment. JAMA. 1994 Aug 24-31;272(8):611-6. — View Citation
Pathak S, Goldofsky E, Vivas EX, Bonagura VR, Vambutas A. IL-1ß is overexpressed and aberrantly regulated in corticosteroid nonresponders with autoimmune inner ear disease. J Immunol. 2011 Feb 1;186(3):1870-9. doi: 10.4049/jimmunol.1002275. Epub 2011 Jan 3. — View Citation
Rahman MU, Poe DS, Choi HK. Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study. Otol Neurotol. 2001 Sep;22(5):619-24. — View Citation
Rynne M, Maclean C, Bybee A, McDermott MF, Emery P. Hearing improvement in a patient with variant Muckle-Wells syndrome in response to interleukin 1 receptor antagonism. Ann Rheum Dis. 2006 Apr;65(4):533-4. — View Citation
Saraçaydin A, Katircioglu S, Katircioglu S, Karatay MC. Azathioprine in combination with steroids in the treatment of autoimmune inner-ear disease. J Int Med Res. 1993 Jul-Aug;21(4):192-6. — View Citation
Sismanis A, Wise CM, Johnson GD. Methotrexate management of immune-mediated cochleovestibular disorders. Otolaryngol Head Neck Surg. 1997 Feb;116(2):146-52. — View Citation
Tebo AE, Szankasi P, Hillman TA, Litwin CM, Hill HR. Antibody reactivity to heat shock protein 70 and inner ear-specific proteins in patients with idiopathic sensorineural hearing loss. Clin Exp Immunol. 2006 Dec;146(3):427-32. — View Citation
Vambutas A, Lesser M, Mullooly V, Pathak S, Zahtz G, Rosen L, Goldofsky E. Early efficacy trial of anakinra in corticosteroid-resistant autoimmune inner ear disease. J Clin Invest. 2014 Sep;124(9):4115-22. doi: 10.1172/JCI76503. Epub 2014 Aug 18. — View Citation
Yamazaki T, Masumoto J, Agematsu K, Sawai N, Kobayashi S, Shigemura T, Yasui K, Koike K. Anakinra improves sensory deafness in a Japanese patient with Muckle-Wells syndrome, possibly by inhibiting the cryopyrin inflammasome. Arthritis Rheum. 2008 Mar;58(3):864-8. doi: 10.1002/art.23261. — View Citation
* Note: There are 20 references in all — Click here to view all references
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Improvement in hearing in comparison to baseline values | An improvement in pure tone average (500 to 3000 Hz) by 10 dB in at least one ear or An improvement of word identification score of at least 12 percent; both relative to baseline values |
24 weeks | |
| Secondary | Pt reported evaluation of auditory acuity | Pt reported evaluation of auditory acuity as measured on a 0-100 Visual Analog Scale (VAS). Patients with a 25% improvement in VAS will be considered responders. | 24 weeks | |
| Secondary | Vertigo evaluation | Vertigo will be evaluated using the validated OTA Dizziness Handicap Inventory (DHI). A change in category is considered clinically significant. | 24 weeks | |
| Secondary | Tinnitus evaluation | Tinnitus will be evaluated using the validated OTA Tinnitus Handicap Inventory (THI). A change of 6 points on this scale is considered clinically meaningful. | 24 weeks | |
| Secondary | Quality of Life assessment | Validated auditory quality of life questionnaire- Response is defined as a 5% or greater improvement | 24 weeks |